Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 182 Show results per page	View Search Criteria \| Help With Results


1.		Prevention of Cyclophosphamide, Hydroxydaunorubicin (Adriamycin), Oncovin (Vincristine), Prednisone/Prednisolone (CHOP)-Induced Chronic Cardiotoxicity

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Supportive care, Treatment				Active				15 to 70				Other				OLSG-0401 NCT00162955


2.		Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old.

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				15 to 60				Other				Hemato INCAN 01/2007 NCT00429065


3.		Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				18 to 70				Other				2006-003750-23 LINFOTARGAM, NCT00466258


4.		LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				65 and under				Other				LAL-Ph-2000 NCT00526305


5.		Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				18 and over				Other				TaCyDexVMP7 NCT00652041


6.		Thalidomide/Dexamethasone Vs MP for Induction Therapy and Thalidomide/Intron A Vs Intron A for Maintenance Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				19 and over				Other				01-002-0601 NCT00205751

Last Modified: 9/16/2008 First Published: 12/1/2000


7.		Phase III Randomized Study of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) With Either Rituximab or Iodine I 131 Tositumomab (Monoclonal Antibody Anti-B1) in Patients With Newly Diagnosed Follicular Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				SWOG-S0016 CALGB-50102, S0016, NCT00006721, ECOG-SWOG-S0016

Last Modified: 8/21/2008 First Published: 9/1/2001


8.		Phase III Randomized Study of Consolidation Therapy With or Without Strontium Chloride Sr 89 After Induction Chemotherapy in Patients With Androgen-Independent Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Any age				NCI				MDA-ID-00156 NCI-3410, 3410, NCT00024167

Last Modified: 9/19/2008 First Published: 10/1/2001


9.		Phase III Randomized Study of Response-Based Chemotherapy With Doxorubicin, Bleomycin, Vincristine, Etoposide, Prednisone, and Cyclophosphamide With or Without Dexamethasone, Etoposide, Cytarabine, Cisplatin, and/or Radiotherapy in Children With Newly Diagnosed Intermediate-Risk Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				21 and under				NCI				COG-AHOD0031 NCT00025259, AHOD0031

Last Modified: 5/18/2007 First Published: 7/1/2002


10.		Phase III Randomized Study of Bleomycin, Doxorubicin, Etoposide, Mechlorethamine, Vinblastine, Vincristine, and Prednisone (Stanford V) Versus Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) in Patients With Previously Untreated Advanced Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 60				Other				BNLI-STANFORDV EU-20206, NCT00041210

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute